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Abstract. The concept of repairing the brain with growth factors has been pursued for many years in a variety of neurodegen-
erative diseases including primarily Parkinson’s disease (PD) using glial cell line-derived neurotrophic factor (GDNF). This
neurotrophic factor was discovered in 1993 and shown to have selective effects on promoting survival and regeneration of
certain populations of neurons including the dopaminergic nigrostriatal pathway. These observations led to a series of clinical
trials in PD patients including using infusions or gene delivery of GDNF or the related growth factor, neurturin (NRTN).
Initial studies, some of which were open label, suggested that this approach could be of value in PD when the agent was
injected into the putamen rather than the cerebral ventricles. In subsequent double-blind, placebo-controlled trials, the most
recent reporting in 2019, treatment with GDNF did not achieve its primary end point. As a result, there has been uncertainty
as to whether GDNF (and by extrapolation, related GDNF family neurotrophic factors) has merit in the future treatment of
PD. To critically appraise the existing work and its future, a special workshop was held to discuss and debate this issue. This
paper is a summary of that meeting with recommendations on whether there is a future for this therapeutic approach and also
what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider in its design.
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INTRODUCTION
The discovery and characterisation of specific
neurotrophic factors in the context of neuronal devel-
opment and synapse formation in the last half of
the 20th century, led to the hypothesis that certain
adult neuronal populations lost to chronic disease
processes might be rescued and potentially regener-
ated by the administration of these agents [1]. This
has been extensively explored in Parkinson’s disease
(PD) with the use of GDNF and related factor NRTN
and the dopaminergic (DA) nigrostriatal pathway- the
loss of which is known to be central and critical to the
development and clinical expression of this condition
[2].
In this short paper, we critically appraise the
pre-clinical and clinical trial work with GDNF and
NRTN in patients with PD. This appraisal is based
on a meeting held over 2 days in August 2019
that brought together experts who had direct and
practical experience in this field. The timing of this
meeting was linked to the recent publication of a
UK-based clinical trial and parallel airing on the
BBC of the two-part documentary “The Parkin-
son’s Drug Trial: A Miracle Cure? [https://www.
bbc.co.uk/mediacentre/proginfo/2019/09/parkinsons
-drug-trial-a-miracle-cure]? The meeting was organ-
ised and funded by The Cure Parkinson’s Trust and
supported by The Michael J Fox Foundation and Van
Andel Institute.
THE PRECLINICAL EVIDENCE THAT
GDNF CAN RESCUE THE
NIGROSTRIATAL PATHWAY
The discovery of GDNF in 1993 was made at a
time of great interest in the therapeutic development
of neurotrophic factors which offered potential for
treating a number of disease states. The search for a
survival factor with high selectivity for midbrain DA
neurons had already been going on for some time.
As such, when Lin et al. reported the cloning and
bioactivity of this new trophic factor in 1993 there
was great excitement [3]. Indeed, this in part helps
explain why there was such a short time span between
the first pre-clinical in vivo studies (performed and
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published in 1994-95) and the first clinical trial with
this agent [4] which started recruiting patients in July
1996.
The second member of the GDNF family of lig-
ands, NRTN, was discovered in 1996 [5] along with
the receptor signaling pathways for these 2 factors
[6]. This work revealed that while GDNF and NRTN
are members of the transforming growth factor beta
(TGF-) family, they signal through a completely
different receptor system compared to other TGF-
family members. GDNF first binds to the glyco-
sylphosphatidylinositol (GPI)-anchored co-receptor
GDNF family receptor alpha-1 (GFR1) and then
the GDNF-GFR1 complex binds to, and activates
the transmembrane receptor tyrosine kinase RET.
NRTN likewise signals to the cells via the RET
receptor, but its binding to RET is mediated through
the GFR2 co-receptor although when delivered at
high levels it also can bind to GFR1[6]. RET then
activates the intracellular mitogen-activated protein
kinase (MAPK), Akt (protein kinase B) and Src sig-
naling cascades that are responsible for the survival
and regeneration of DA neurons. It is important to
stress that GDNF and NRTN trigger rapid responses
in DA neurons through protein phosphorylation, but
in addition to that they activate a number of tran-
scription factors that have longer-lasting effects on
DA neurons
The initial work with GDNF was made possi-
ble through having access to a recombinant human
form of protein from Synergen and Genentech. This
enabled the generation of preliminary in vivo data
on DA neuroprotection in the three rodent PD mod-
els available at the time: the rat 6 hydroxydopamine
(6-OHDA) model [7, 8], the mouse 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model
[9] and the knife-transection model [10]. In addi-
tion, a study performed in intact rats showed that
GDNF, administered into the substantia nigra, could
stimulate DA neuronal function [11]. The fact that
the findings from all of these studies provided posi-
tive evidence in the same direction was re-assuring –
namely a growth factor that seemed to work on DA
neuronal rescue and regeneration.
These initial preclinical studies used intracere-
bral administration of GDNF, (single or repeated
injections of microgram amounts over the substan-
tia nigra). Nevertheless, Amgen, the company that
had acquired the rights to GDNF, opted for an
intraventricular delivery approach in its first clin-
ical trial [4] (see below). A critical factor in this
decision were the results of a study, sponsored by
Amgen, reporting significant, dose-dependent ben-
eficial effects obtained by monthly intraventricular
injections of GDNF in MPTP-treated rhesus mon-
keys [12]. The results again looked promising: all the
major motor features (bradykinesia, rigidity, posture
and balance) were improved when assessed 4 weeks
after the last (fourth) monthly injection. Doubts on
this mode of administration, however, soon arose:
studies on the distribution of GDNF after intraven-
tricular delivery indicated very limited diffusion into
the brain parenchyma given its strong binding to
extracellular matrix and cell surface heparin sulphate
proteoglycans [13, 14]. Furthermore, a follow-up
study by another team, performed in the same mon-
key model, failed to show any protective effect on the
MPTP-lesioned DA neurons [15].
While this trial was ongoing, experimental work
performed in rodent and primate PD models pro-
vided further and more compelling evidence that
GDNF must be administered directly into the brain
parenchyma to exert its actions, and that the site, dose
and timing of GDNF delivery are important. Experi-
ments in 6-OHDA lesioned rats showed that delivery
into the substantia nigra could rescue DA neuronal
cell bodies against toxic damage but failed to protect
their axonal projections in the striatum [16]. Res-
cue of both DA neuronal cell bodies and their axons
projecting to the striatum required that the factor be
delivered into the striatum, or into both the striatum
and substantia nigra, provided that it is given before
or soon after the toxin treatment [17]. Furthermore,
the timing of the delivery of GDNF was also found
to be important. In both rodents and primates there
was evidence that delayed intrastriatal GDNF deliv-
ery, starting weeks or months after 6-OHDA or MPTP
treatment, could still protect surviving DA neurons
and stimulate regenerative sprouting from spared
axons in the partially denervated striatum [18–21].
Based on all this experimental data it was con-
cluded that the therapeutic potential of GDNF is
due to a combination of three interacting mecha-
nisms: 1) Protection of midbrain DA neurons against
toxin-induced cell death; 2) stimulation of axonal
regeneration in the area reached by GDNF; and 3)
recovery of function through up regulation of DA
turnover and release.
These experimental studies, performed over the
first decade after GDNF’s discovery, were very
encouraging and stimulated a series of clinical trials,
including some where the agent was given intra-
putaminally (see below). At that time, the preclinical
data seemed to support such a move to the clinic
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based on all the studies performed in mice, rats and
non-human primates. There were, however, obvious
weaknesses in the pre-clinical data: Firstly, GDNF
was relatively ineffective in the face of severe lesions
giving >80% loss of DA neurons which more closely
mimics the human condition. Secondly, the data
showing efficacy was obtained in toxin-based models
where 6-OHDA or MPTP are administered acutely
which results in a degenerative process that is pri-
marily driven by oxidative damage or mitochondrial
dysfunction not protein aggregation. Further, these
models do not replicate the late stages of PD nor
the progressive, alpha-synuclein related pathophys-
iology that is characteristic of the human disease.
Given this difference, there was a concern that the
results obtained in toxin-based models may not be
predictive for human PD patients receiving this exper-
imental therapy. In addition, there were also concerns
about whether the GDNF made at that time using E.
coli (as opposed to human recombinant protein made
in mammalian cells) would work less well in human
patients.
Some of these anxieties have been borne out in
more recent experiments. Over the last few years
the access to alpha-synuclein-based PD models has
allowed this first question to be further explored [22].
These models not only offer better opportunities to
more faithfully replicate the alpha-synuclein related
pathology seen in people with PD, but the lesions so
induced evolve slowly over time in contrast to the
far more rapid time course of acute toxin models of
PD. Using such alpha-synucleinopathy models, stud-
ies designed to reproduce the type of neuroprotective
and restorative effects of GDNF, consistently seen in
MPTP and 6-OHDA models, have so far failed [23,
24].
In a follow-up study performed in the AAV-
alpha-synuclein model [25], Decressac et al. (2012)
suggested that this could be due to a failure of alpha-
synuclein overexpressing nigral neurons to respond
to GDNF. This, the authors postulated, could be
due to down regulation of the GDNF receptor RET,
mediated by a reduced expression of the DA related
transcription factor, nuclear receptor related 1 protein
(Nurr1). Nurr1 is known to regulate RET expres-
sion in DA neurons [26] and the two are thus closely
related.
In human PD postmortem material, Nurr1 has been
shown to be down-regulated in DA neurons that
over express alpha-synuclein [27] and a similar down
regulation of Nurr1 is also seen in alpha-synuclein
overexpressing neurons in the AAV model of PD.
This, in turn, is accompanied by a marked reduc-
tion in the expression of RET [25]. The dependence
on Nurr1/RET expression is further supported by an
experiment performed in Nurr1 deleted mice show-
ing that the ability to respond to GDNF is abolished
in DA neurons lacking Nurr1 [25].
The findings obtained in the AAV-alpha-synuclein
model should however be interpreted with caution.
The cellular levels of alpha-synuclein obtained in this
model are artificially high (4-5-fold above normal)
and thus may not reflect the milieu in the affected DA
neurons in the PD brain. Furthermore, showing that
RET expression is reduced in the human PD brain
has proven inconclusive (see Su et al. 2017 for a
dissenting view [28]).
In summary, the preclinical data suggests that
GDNF can rescue DA neurons and their projections
in the nigrostriatal pathway in a range of toxin animal
models but the ability to rescue may be different in
the context of the alpha synuclein pathology that is
seen in the brain of people with PD.
THE EARLY CLINICAL TRIALS
The move from the lab to the clinic is always chal-
lenging and in order to assess progress and success,
new agents are often evaluated against four key ele-
ments. These include whether the drug (in this case
GDNF for PD):
• Reaches its proposed site of action at sufficient
concentrations (namely the DA nigrostriatal
pathway);
• Shows target engagement at that site in a mea-
surable way (GFRa1/RET signalling leading to
positive changes in this DA system);
• Displays functional downstream pharmacolog-
ical effects (shows sprouting, growth and /or
survival of DA fibers/synapses in the presence
of an ongoing degenerative disease process);
• Exhibits improvement in the relevant phenotype
of the treated individuals (better motor perfor-
mance around measures known to be sensitive
to this DA network).
The first of these criteria falls under the umbrella of
delivery, the latter three provide a basis for potential
efficacy, if delivery sufficient to cover the putamen
can be achieved. In the sections below, we consider
the open-label and double-blind, placebo-controlled
clinical trials to-date in which recombinant human
GDNF has been directly administered to people with
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PD. This will be followed by a description and dis-
cussion of the clinical studies where a related trophic
factor NRTN was administered as viral vector injec-
tions to the basal ganglia as well as an ongoing GDNF
gene therapy trial.
The initial double-blind randomised control trial
of intracerebroventricular injections of GDNF
protein
The first clinical trial of GDNF was conducted
by Amgen and was a multicentre, randomized,
double-blind, placebo-controlled study of intracere-
broventricular (ICV) administration of GDNF [4].
Monthly ICV injections were given via an intraven-
tricular cannula inserted in the right frontal horn using
standard stereotactic techniques. This was a dose
escalation study with five dosage arms (25g, 75g,
150g, 300g, and 4000g) with 7-8 patients
receiving active drug and 2-3 patients receiving
placebo for a period of 8 months followed by an
open-label extension period of up to an additional
20 months giving maximum single doses of up
to 4000g in 16 subjects. The primary outcome
variables, the change in “practically defined OFF”
and ON motor Unified Parkinson’s Disease Rating
Scale (UPDRS) scores, were not significantly dif-
ferent from placebo in any of the active treatment
groups apart from a mild but significant worsening
in OFF scores in the 75g group and ON scores in
the 300g group. Adverse effects were more com-
mon in the active treatment groups and included
anorexia, weight loss (>5% body weight), hypona-
tremia and the unexpected finding (at the time) of
sensory symptoms such as paraesthesia and Lher-
mitte’s phenomenon.
Although the adverse effect profile indicated that
GDNF administered by ICV injection was having
biological effects (the anorexia and weight loss were
thought to be due to its action in the hypothalamus),
this approach did not improve the clinical state of the
patient.
It was postulated that this lack of benefit could
relate to a failure of GDNF to reach and mediate
effects in the target tissue (putamen and indirectly
the substantia nigra) [4]. Supporting this hypothe-
sis was a report of the postmortem assessment of a
single patient from this trial [29]. In contrast to exper-
iments in monkeys, where GDNF immunoreactivity
was observed within the caudate nucleus ipsilateral
to the infused ventricular frontal-horn and in the
septum bilaterally (although whether this was suf-
ficient to activate RET signalling was not assessed),
the human postmortem evaluation demonstrated no
intra-parenchymal diffusion of GDNF across the
cerebrospinal fluid:brain barrier from the ventricu-
lar cavity to the relevant basal ganglia structures. As
such, it was to be expected that the autopsied tissue
failed to demonstrate evidence of significant regen-
eration of nigral neurons and their fibres [29].
While this first in-human trial failed to hit its
primary end point, the above results showed that
monthly infusions of a biologic-agent unable to pen-
etrate the blood-brain-barrier was well tolerated and
“relatively” safe even when high doses of GDNF were
given (4000g) [4]. However, the lack of parenchy-
mal penetration coupled with an absence of motor
benefit led on to further trials with infusions directly
to the putamen.
The initial open label trials of intraputaminal
Injections of GDNF protein
To ensure that GDNF reached the DA termi-
nal plexus within the posterior-dorsal striatum, two
small open label studies evaluated direct-to-putamen
continuous (rather than bolus) catheter infusions
of GDNF [30, 31]. To effect continuous infusions,
GDNF was administered from subcutaneous pumps
placed in the abdomen connected to a single catheter
to each putamen in a 5-patient cohort in Bristol, UK
and to a single-sided unilateral catheter only in a 10-
patient cohort studied in Kentucky, USA. The Bristol
group initially reported after 6 and 12 months as did
the Kentucky group [30, 31]. Doses in the Kentucky
study were escalated to 30g per day and in the
Bristol trial, patient’s doses were on average 30g
per day. Some patients did receive even higher doses
(>30g GDNF per day) but this produced high sig-
nal changes on MRI in the putamen—changes which
resolved with dose reduction.
Both of these small open label studies reported
marked benefits in UPDRS motor (part III) scores in
the practically defined OFF state with a mean reported
improvement of approximately 30%–40%. Changes
in diary fluctuations were equally encouraging at this
open-label stage [30, 31] although it should be noted
that the changes were bilateral even in patients who
had been in receipt of unilateral infusions for reasons
that are not clear.
In the Bristol study, 18-fluorine-dihydroxypheny-
lalanine ([18F]DOPA) positron emission tomography
(PET) scans showed an increase in tracer uptake
mainly around the catheter tip, which potentially rep-
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resented sprouting of remaining terminals, supported
in part by a subsequent single case postmortem study
[32].
In the Kentucky study, there was one serious
adverse event (SAE) when the catheter became
exposed which was associated with oedema around
the catheter track in the putamen of this same patient.
Three patients reported mild tingling sensations in the
forehead, neck and lower back and two patients expe-
rienced transient Lhermitte’s phenomenon. Seven
patients developed antibodies to GDNF without clini-
cal sequelae. High resolution MRI scans revealed that
there was no evidence of GDNF-induced cerebellar
toxicity, which became more of a concern in some
of the later preclinical non-human primate studies
with GDNF (see below). Finally, all improvements in
UPDRS scores were lost within 9-months of stopping
the GDNF infusions.
Based on these encouraging open label observa-
tions, a prospective, double-blind, placebo-controlled
trial of continuously infusing GDNF to the putamen
was initiated.
DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIALS
The Amgen trial
Amgen sponsored the first double-blind trial
involving direct intra-putaminal delivery of GDNF. In
this multicentre trial, patients were randomized 1 : 1
to receive bilateral continuous intra-putaminal infu-
sions of either GDNF at a dose of 15g/putamen/day
or placebo [33]. One catheter was stereotactically
placed on each side with its tip targeted to the
posterior-dorsal putamen and attached to a separate
SynchroMed pump (Medtronic), implanted subcu-
taneously over the patient’s abdomen. The primary
end point was the change in UPDRS motor score in
the practically defined OFF condition at 6 months.
Secondary end points included other UPDRS scores,
motor tests, dyskinesia ratings, patient diaries, and
[18F]-DOPA uptake on PET imaging. Patients were
stratified by baseline UPDRS OFF motor score
(<44, >45) and 30 subjects (15 in each group) were
calculated to be needed to give a 90% power to
detect a between group difference of 25% in the
percent change in UPDRS OFF motor score.
34 patients were implanted and randomized; 17
received GDNF (all completed the trial), and 17
received placebo (with 16 completing the trial, and
one discontinuing due to pump site infection). At 6
months, the mean percentage change in OFF UPDRS
motor score was –10% in the GDNF group com-
pared to –4.3% in the placebo group which was not
statistically significant. Secondary end point results
were also similar between the groups. There was no
significant relationship between the change in motor
scores and the catheter tip location. In the two thirds
of paired evaluable PET scans (1/3 of paired scans
were excluded due to head movement artefact) there
was a 32.5% treatment difference favouring GDNF
in mean [18F]DOPA influx constant (p = 0.019) but
this did not correlate with changes in the OFF
UPDRS motor scores. Procedure- and device-related
complications were not uncommon while treatment
related complications were infrequent. The marked
anorexia and weight loss observed in the higher dose
ICV study were not seen. Serious, device-related
adverse events required surgical repositioning of
catheters in two patients and removal of devices in
another [33].
Three patients, one in the double-blind phase and
two in the open label extension, developed neu-
tralizing anti-GDNF antibodies—again without any
obvious clinical sequelae- which may relate to the
way the GDNF was delivered with leakage to the
periphery, and activation of the immune system.
Furthermore, contemporaneously, new toxicologi-
cal studies in non-human primates (NHPs) found
focal limited loss of Purkinje cells and near com-
plete loss of molecular and granule cell layers in
3/5 monkeys rapidly withdrawn from 3 months of
unilateral infusions of much higher doses of GDNF
(100g/putamen/day) while one monkey continuing
on treatment was found to have milder cerebellar
cortical pathology [34].
As a result of this combination of a negative clin-
ical double-blind placebo-controlled trial result, the
finding of neutralizing antibodies in a small number
of patients and concerns about the NHP toxicological
findings, Amgen chose to terminate their GDNF pro-
gram for PD. This led to a vigorous debate between
various researchers and patient groups as to why
the double-blind trial and the open-label studies had
come to different conclusions. These included:
1. The potential for a major placebo effect in open-
label trials given it involved an invasive surgical
approach and problems in maintaining true clin-
ical equipoise. However, it should be noted that
in the double-blind study there was no major
placebo effect, but rather an absence of a posi-
tive clinical effect in either group.
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2. Differences in dosages given, in particular
higher doses were generally used in the open
label studies, although benefit had also been
claimed with lower doses in these early studies;
3. Differences in delivery including catheter
dimension and design. In general, catheter
dimensions including its external diameter,
design (no step, stepped or recessed stepped)
and number of catheters inserted along with
implantation technique could all have an effect
on the extent to which the agent was delivered
and remained at the target site. In addition, dif-
ferences in the diffusion of the agent across the
target structure could also have impacted on
the total volume of putaminal tissue exposed to
study drug (see below) [35] and thus its poten-
tial therapeutic effectiveness. All of this has led
to the development of new convection enhanced
delivery systems (see below).
4. Differences in the patients selected for trials,
in particular whether more advanced patients
with more severe DA losses were recruited to
the double-blind study.
Given this uncertainty, there was a feeling in some
quarters that this therapy should not be abandoned
at this stage, a position reinforced by further obser-
vations from the original open-label Bristol cohort
[32, 36, 37]. This included the fact that the origi-
nal five subjects who continued to receive continuous
infusions from 12 to 24 months and beyond, all main-
tained their improved UPDRS part II and part III
OFF scores compared to baseline, consistent with
their improved [18F]DOPA PET data [36]. Finally,
one subject who had been infused continuously for 39
months and then reviewed at 36 months after GDNF
cessation, continued to experience a major clinical
benefit. This benefit was accompanied by [18F]DOPA
PET putaminal uptake that continued to show an
improvement compared to pre-treatment scans [37].
Although a single case, this did support the concept
that GDNF might still work if methodological aspects
of its administration were improved. Thus, a new
GDNF trial was proposed.
The recent Bristol study
This new double-blind investigation of directly
administered GDNF took the form of a randomised,
placebo-controlled, single-centre trial sponsored by
the UK National Health Service (and funded by
Parkinson’s UK and The Cure Parkinson’s Trust)
which started in 2012 [38] (NCT03652363). Patients
selected were 35–75 years old, had motor symptoms
for 5 or more years, with moderate disease sever-
ity in the OFF state (Hoehn and Yahr stage 2–3 and
a UPDRS motor score between 25–45) and motor
fluctuations (average of at least 2.5 hours of OFF
time per day on 3-day fluctuation diaries). They all
had marked levodopa responsiveness as defined by
a > 40% improvement in UPDRS motor score follow-
ing a levodopa challenge after a practically defined
OFF period. Importantly, the major difference with
this trial with what had gone before was the use of
a new delivery device designed to establish greater
coverage of the putamen.
Once implanted with this new intermittent
enhanced drug administration system that enabled
convection enhanced delivery (CED), patients were
randomised. Post-randomisation, patients received
a total of 10 study treatments at 4-weekly inter-
vals (Weeks 0 to 36). At each treatment, 400L
of infusate (300L GDNF or placebo, followed by
100L aCSF) was delivered per catheter into the
post-commissural putamen at a GDNF concentra-
tion of 0.2g/L. Thus, the total GDNF dose given
every 4 weeks was 240g (120g/putamen given as
60g/catheter).
The results of this trial were published in February
2019 [38] and they revealed that the trial did not reach
its prespecified primary endpoint; the mean OFF state
UPDRS motor score decreased by 17.3 ± 17.6% in
the active group and 11.8 ± 15.8% in the placebo
group. A range of secondary and supplementary
efficacy endpoints also failed to show significant dif-
ferences between the groups as well. In contrast to the
non-significant clinical results, the [18F]DOPA PET
findings were positive. Between baseline and week 40
there was no change in the placebo group, whereas
in the GDNF group there were significant changes
across the putamen (in a graded fashion ranging from
25% anteriorly to 100% in the posterior putamen) but
not in the caudate (which acted as an internal control).
These marked relative percentage increases, while
statistically significant, still meant that the absolute
improvement was only to a level that was 50–60%
of that seen in the normal intact posterior putamen
which may explain why the treatment did not result
in significant clinical changes.
At the conclusion of this double-blind study, all
patients had the chance to enrol into an open label
extension trial that used the same GDNF dose regi-
men and intermittent infusion parameters as for the
initial double-blind study. This open label extension
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trial, also lasted 40 weeks, and was initiated before
the results from the double-blind parent investiga-
tion were known. It was undertaken primarily to
gain longer term safety data and to gather further
exploratory information on GDNF clinical effects
over a more prolonged period of repeated tissue expo-
sures [39].
The primary endpoint of this extension study
was the percentage change from baseline (Week 0)
to Week 80 in the practically defined OFF state
UPDRS motor score, comparing the group that had
received GDNF in the initial trial followed by open-
label GDNF (GDNF/GDNF) versus the group that
received placebo in the parent investigation followed
by open-label GDNF (placebo/GDNF) (in effect a
delayed-start design). Secondary endpoints included
absolute change from baseline in OFF and ON state
UPDRS part II and part III scores and change from
baseline in diary ratings. A further pre-specified
secondary endpoint included comparing Week 80
UPDRS scores in the GDNF/GDNF group against
Week 40 scores in the placebo/GDNF group (i.e., at
the end of the placebo treatment).
All 41 parent study participants were enrolled into
the extension study, and all were included in the anal-
yses. Again, there were no significant differences.
Comparing baseline (Week 0) to the end of treat-
ment (Week 80), the OFF state UPDRS motor score
improved by 26.7 ± 20.7% (mean ± standard devia-
tion) in the GDNF/GDNF group and by 27.6 ± 23.6%
in the placebo/GDNF group. Likewise, none of the
secondary or supplementary outcomes spanning the
entire 80-week period were significantly different
outside changes in L-DOPA equivalent dose (the
increase in the daily L-DOPA equivalent dose from
baseline to Week 80 was smaller in the GDNF/GDNF
group (59 ± 194 mg) than in the placebo/GDNF
group (289 ± 365 mg) [35].
Treatment emergent adverse events (TEAEs,
events commencing post initiation of GDNF or
placebo infusions) were reported for all 41 patients.
No patient had a TEAE that led to discontinuation of
study medication. Of the eight serious TEAEs, three
were considered to be device related and included
two occurrences of a hypertrophic skin reaction
around the port site that required surgical skin thin-
ning and a possible port site infection that occurred
approximately 15 weeks into the treatment phase and
required inpatient treatment with oral antibiotics.
Two patients enrolled into the double-blind study
did not proceed to randomisation and were withdrawn
prior to the start of treatment because they failed
the post-surgery eligibility criteria. One patient expe-
rienced a mildly symptomatic putaminal ischemic
stroke coincident with the initial test infusion. The
patient recovered completely but was withdrawn to
avoid unnecessary risks. The second patient suffered
a small asymptomatic haemorrhage in both putamina
during the initial test infusion.
Blood sample analyses showed no measurable
GDNF plasma concentrations and no GDNF-binding
serum antibodies in GDNF-treated patients at any
point. This contrasts with the double-blind Amgen
study and the earlier open label studies and may
relate to the different delivery devices and delivery
regimens that were used in each trial.
In summary, these two studies have shown that
direct infusions of GDNF administered in a man-
ner to achieve CED can be given every 4-Weeks
over 18 months in a fashion that patients found
tolerable. Employing this approach, as evidenced
by a combination of direct Gadolinium infusion
through the delivery system and improvement in
[18F]DOPA PET uptake, appeared to achieve accu-
rate and whole putamen-wide target tissue delivery
with some evidence of target receptor engagement
using PET imaging. Despite this apparent optimisa-
tion of delivery, however, the clinical primary and
secondary endpoints in both trials were negative.
Whilst the partial restoration in PET signal may alle-
viate some of the concerns around insensitivity to
GDNF in the face of an alpha-synucleinopathy or that
patients more than 5 years from the point of diagno-
sis have no terminals left to restore, the fact remains
that improvement in [18F]DOPA PET signal cannot
be used as evidence for improvement in functional
pharmacology, especially as this tracer has also been
said to label inflammation [40]. Questions therefore
remain over whether the lack of significant benefit
in placebo-controlled trials to date reflects therapeu-
tic ineffectiveness or whether this would be resolved
with an increased dose and exposure of mammalian
cell made GDNF coupled to treating patients with
earlier stage disease.
GENE THERAPY TRIALS WITH NRTN
AND GDNF
In contrast to the immense logistical challenges
and potential safety concerns associated with contin-
uous or repeated long-term delivery of recombinant
GDNF protein, gene therapy promises sustained,
durable and localized production of properly folded
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biologically active GDNF following a one-time dos-
ing procedure. Several clinical studies have now been
conducted in PD, including a multi-phase program of
NRTN gene transfer, a homolog of GDNF, and more
recently a Phase 1 clinical safety trial of GDNF gene
transfer. Both the NRTN and GDNF gene therapy
programs utilized gene transfer vectors derived from
the non-pathogenic adeno-associated virus serotype
2 (AAV2) with a constitutive CMV promoter. These
vectors appear to have a favourable safety profile for
neurotrophic factor gene delivery in PD, in addition
to which AAV2 has an exclusive neuronal tropism
and restricted distribution when directly delivered to
the brain [41], thus minimising off target side effects.
The initial preclinical studies exploring this
approach demonstrated that GDNF and NRTN
gene delivery conveyed efficient protection against
MPTP/6-OHDA lesions when the gene transfer was
performed prior to, or shortly after, neurotoxin expo-
sure. However, in an attempt to more closely mimic
both early and later stages of PD a more refined MPTP
model was developed in non-human primates (NHPs
[21, 42]). Using this model, animals with established
parkinsonian signs were randomized to receive either
1) AAV2-GDNF (9.9 × 1011 vector genomes, vg;
n = 8), or 2) sham PBS (n = 7) intraputaminal infu-
sions via CED [21], and were followed for 1, 6, 14,
or 24 months.
In one of these NHP studies, it was demon-
strated that there were marked functional motor
improvements following AAV2-GDNF (mean 56%
reduction of motor rating scores) in both the mod-
erately and severely lesioned MPTP monkeys. This
motor recovery directly correlated with increased 6-
[18F]Fluoro-L-M-tyrosine (FMT) PET uptake that
remained stable throughout the 24-month time point
and which also correlated with enhanced dopamine
and dopamine metabolites when assayed from tis-
sue homogenates from these same animals. Increased
tyrosine hydroxylase-immunoreactive (TH-IR) fibre
density was also seen in the partially lesioned hemi-
sphere (equivalent to “early” PD) receiving the
AAV2-GDNF but was much less prominent in the
severely lesioned side (comparable to advanced PD).
Together these findings suggested that intraputaminal
infusions of AAV2-GDNF were safe and that greater
parenchymal GDNF levels (∼24 ng/mg protein) were
well-tolerated, without the adverse effects seen with
protein infusions of GDNF (e.g., weight loss) [4,
33]. This also indicates that GDNF is capable of
restoring dopaminergic terminals with an associated
significant recovery of motor function, particularly
in the partially lesioned conditions. In addition, there
was strong evidence that GDNF delivery provided
greater potential for intrinsic TH-IR positive sprout-
ing in earlier rather than later stages of nigrostriatal
degeneration.
These and related studies [43] also found that there
was anterograde transport of AAV2-GDNF, via direct
and indirect connections, which was independent
of the degenerating nigrostriatal dopaminergic (DA)
neurons [43, 44] and their capacity to retrogradely
transport GDNF protein. This mechanism resulted
in the broad expression of GDNF from the putamen
to the substantia nigra (SN) pars reticulata, despite
varying degrees of nigrostriatal DA neurodegenera-
tion and raised the potential that this therapeutic may
provide distinct advantages through rebuilding DA
nigrostriatal networks within the PD brain.
This NRTN preclinical work led to clinical tri-
als that were performed by Ceregene Inc. using
the AAV-2 serotype and the NRTN transgene, the
first of which was an open label clinical trial [45]
(NCT00252850). Twelve patients aged 35–75 years
with a diagnosis of PD for at least 5 years, in
accordance with the Parkinson’s UK Brain Bank
Criteria, received bilateral, stereotactic, intraputami-
nal injections of AAV2-neurturin (CERE-120). The
first six patients received doses of 1.3 × 1011 vec-
tor genomes (vg)/patient, and the next six patients
received 5.4 × 1011 vg/patient. The treatment was
well tolerated with no side effects and a number of
clinical endpoints suggested improvement. However,
disappointingly there was no increase in 18F-DOPA
uptake on PET imaging.
This initial trial was followed by a multi-centre
randomized (2 : 1) double-blind trial comparing intra-
putaminal injections of AAV2-neurturin to sham
surgery in 58 PD patients [46]. An infusion volume
of 40l of vector was injected into each putamen
with subjects in the active treatment arm receiving a
dose of 5.4 × 10¹¹ vg/patient. Disappointingly, there
was no significant difference between the two groups
based on UPDRS Part III motor scores in the OFF
state at 12 months post-transduction, the primary
endpoint. However, a significant placebo effect was
noted, with a 6-point reduction in UPDRS seen at 3
months in the sham group, which persisted for the
duration of the study. However, a pre-specified post-
hoc analysis suggested that those patients blindly
assessed at the 15–18 months post-treatment time
point may have had some benefit, although there was
no controlling for multiple comparisons. In addition,
it should be noted that the whole cohort could not be
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followed blindly out to these time points due to the
ending of the trial and the blind being broken at 12
months. This may have created a bias in the effect
seen.
Histological data from patients who died from
events unrelated to the procedure, indicated that
NRTN was being expressed within the vicinity of the
injection sites, and that this resulted in focal upreg-
ulation of TH, but to an extent that was probably
insufficient to provide any clinical benefit. Addition-
ally, there was very limited NRTN seen in nigral
neurons, suggesting that the severity of the nigrostri-
atal axonopathy in these advanced PD patients did not
allow sufficient retrograde transport of NRTN to the
nigral perikarya to provide neurorestorative effects
[47].
Based on the small area of transduction, the lack
of NRTN expression in nigral neurons, the perceived
defect in retrograde transport and the potential for
changes to occur at a longer time-point, a second ran-
domized double-blind trial comparing higher putam-
inal volumes plus a direct injection into the nigra
was undertaken [48]. Fifty-one patients were enrolled
in this multi-centre trial and randomly assigned
(1 : 1) to receive either bilateral AAV2-NRTN (180l
injection volume per hemisphere) into the substan-
tia nigra (2.0 × 1011 vg/patient, 15L × 2 infusions)
and putamen (1.0 × 1012 vg/patient, 50L × 3 infu-
sions), or sham surgery. Again, no statistically
significant clinical differences were seen in UPDRS
Part III motor OFF scores at 15-months (primary
endpoint) between the active treatment and sham
operated arms.
Following the NRTN studies, an open-label, dose-
escalation Phase 1 study of AAV2-GDNF was
initiated in 2013 (NCT01621581) [49]. In this GDNF
gene therapy study, 13 (of an intended 24) partici-
pants with advanced PD received bilateral magnetic
resonance imaging (MRI)-guided, CED intraputam-
inal infusions of AAV2-GDNF (9 × 1010 (n = 6),
3 × 1011 (n = 6), 9 × 1011 vg (n = 1); delivered in
a 450L volume per putamen. Safety and tolera-
bility of AAV2-GDNF intraputaminal delivery by
CED was confirmed by real-time MRI and postop-
erative monitoring, with no serious adverse events
(SAEs) attributed either to the procedure, or to the
investigational product. Increased PET uptake values
of 18F-DOPA were noted at the documented infu-
sion sites at the 6-month time point as compared
to baseline values, with further enhanced uptake
observed at 18-months post-treatment time point.
A trend was noted for earlier and more marked
increases in patients with shorter disease duration.
No significant differences were seen at 18-months
between the three treated cohorts in terms of their
UPDRS Part III motor scores or total levodopa equiv-
alent doses. The unchanged PD motor scores and
stabilisation of their anti-parkinsonian medications
following putaminal AAV2-GDNF delivery might
support possible biological effects of this therapy
in participants with advanced PD but this remains
unproven.
Several key changes were made as part of the
AAV2-GDNF Phase 1 study design compared to prior
direct infusion studies in PD conducted in the early
2000s, including:
a) the use of intraoperative MRI-guidance, and
gadolinium co-infusion with AAV-GDNF
b) using a reflux-resistant delivery cannula with a
stepped design to increase distribution within
the target putamen while reducing off-target
leakage;
c) allowing the visualisation and monitoring of
CED infusions in real-time with an ability to
surgically modify the cannula position and infu-
sion parameters to maximise the putaminal
coverage, and
d) increasing the infusion volumes up to 450L
per putamen, 3 times greater than the volume
delivered in the Phase II AAV2-NRTN study
[46, 48].
Despite these key modifications in methods, the
average putaminal volumetric coverage documented
by retrospective interim analysis of MRIs was only
26%, much lower than that anticipated to be required
for a meaningful clinical benefit. In part, this lim-
itation in putaminal coverage may have been due
to the transfrontal surgical approach to the puta-
men, where the trajectories are perpendicular to the
long axis of the target volume. This inability to
broadly cover the putamen with this standard surgical
approach may have also been a relevant disadvan-
tage in the AAV2-NRTN and earlier recombinant
GDNF protein infusion studies, where there was
minimal putaminal transgene expression or effects
with small localised changes relative to the radio-
graphic improvement displayed via18F-DOPA PET
imaging.
Although long term follow-up for the Phase 1
adeno associated virus (AAV) 2-GDNF cohorts is
ongoing, enrolment was closed following the interim
analysis, due to the insufficient putaminal coverage
(mean of 26%).Other studies of a AAV2-L-aromatic
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Fig. 1. Transfrontal versus Posterior (occipital) trajectories utilizing CED. MRI-guided stereotactic approaches for vector delivery to the
putamen utilizing convection enhanced delivery (CED) and stepped cannulae. This approach allows for precise targeting, shape-fitting
infusions, and larger delivery volumes to improve the extent of transduced putaminal tissue, thereby increasing transgene production
capacity. With the transfrontal approach, the cannulae are oriented to the short axis of the putamen limiting vector coverage to <30%, often
requiring 2-3 tracts. The posterior (occipital) approach maximizes the delivery by paralleling the putaminal long-axis, requiring only 1 tract,
which achieves >50% putaminal vector coverage with larger infusion volumes.
amino acid decarboxylase (AADC) gene therapy for
PD [50], however have shown that delivering vol-
umes up to 1800L per putamen using a CED
approach is feasible with a good safety profile and
providing putaminal volumetric coverage of >50%.
More importantly, this AAV2-AADC PD gene ther-
apy investigation has provided convincing evidence
that the clinical benefit improved concurrently with
increases in volume of vector delivered and thereby
the extent of putaminal coverage. These findings
underscore the importance of optimising the trans-
duced tissue volume and putaminal infusion coverage
as factors correlating directly with clinical efficacy in
PD [49].
These latter efforts have prompted the design of
a new Phase 1b trial to assess a higher dose of the
AAV2-GDNF therapeutic in moderately advanced
PD patients, (similar to those in Phase 1), as well as in
subjects with early disease (namely within 5 years of
PD onset). Furthermore, this new study will be using
a posterior (occipital) trajectory to each putamen,
(paralleling the long axis), that allows shape-fitting
CED of higher infusion volumes, thereby improv-
ing putaminal coverage and GDNF production levels
more uniformly throughout the putamen [51].This
posterior putaminal approach is similar to that
recently reported in the GDNF protein infusion study
[38] and has also been safely performed using MRI-
guidance and CED, in the ongoing AAV2-AADC
study (NCT03562494) (see Fig. 1).
WHERE NEXT?
The question as to whether GDNF has a compet-
itive future in the treatment of PD is still unclear. A
number of conclusions can be drawn from the stud-
ies undertaken to date with GDNF and related factors
(see Table 1) along with a number of recommenda-
tions about what another trial with GDNF should
consider and thus might look like (see Table 2).
Table 1
Summary of main findings on the effects of GDNF and related
factors in models and clinical trials in PD
• Studies have shown a statistically significant response in some
patients, but these are not consistent, and the majority of studies
have been negative in terms of reaching their primary outcome;
• Striatal dopamine has increased in most patients in receipt of
GDNF as evidenced using 18F–dopa PET imaging;
• There is little evidence of sufficient retrograde transport of
GDNF/NRTN to the substantia nigra in patients when the agent
is delivered into the striatum;
• Postmortem studies show that where there is expression of
GDNF/NRTN there is some upregulation of TH.
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Table 2
Factors to consider in future clinical trials with GDNF and related factors in PD
What form should the GDNF be given in?
• A gene therapy approach was favoured over protein infusions given the complexity of the neurosurgical intervention required for the
former and the burden this places on the patients with Parkinson’s disease.
• Consider using mammalian cell produced GDNF and NRTN proteins.
Patient type
• Younger patients with marked L-dopa response and no major ventral striatal dopamine loss on dopamine imaging.
• Avoid certain genetic forms/variants associated with Parkinsonism (Parkin; GBA).
Disease stage
• Avoid late stage disease.
Dose given
• Depends on the neurotrophic factor that is being delivered, but probably need higher doses than have been trialed to date (with the
exception of the first ICV trial of GDNF).
Volume given
• Depends on delivery system but need to give up to ∼1 ml per striatum treated.
Delivery device
• Several now in existence, e.g., Renishaw, Clearpoint system.
Need for adjunct therapies
• Not proven to be needed, although preclinical data suggests that Nurr 1 agonists may enhance the efficacy of GDNF—so perhaps this
should be included as part of further trials.
Need for imaging? If so with what?
• F-dopa PET imaging seems to have provided useful information in trials to date, but need for other PET markers looking at DA
turnover/release as well as network reconstruction.
Trial end points: What and when?
• Standard measures UPDRS part 2 ± PDCore scores at 18–24 month as the primary end point.
• Sample size currently undecided given lack of major effects seen to date which would allow one to power such a study.
Trial design
• Consider a delayed start design to the trial or a randomized double-blind placebo-controlled study.
• Keep the trial outcomes and measures simple.
• In postmortem samples, it is important to show that GDNF and NRTN have activated RET-dependent signalling pathways or to show
direct RET receptor activation.
Health economics for this agent?
• Depends on where it is positioned
BUT although it works uniquely to restore the dopaminergic nigrostriatal, it will nevertheless have to compete with other “DA”
therapies/interventions- new dopamine drugs; DuoDopa®; Deep Brain Stimulation etc and the newer dopaminergic gene or cell-based
therapies should they be shown to work.
• Currently it would not be competitive given the size of effects seen to date, but this may relate to suboptimal delivery, etc.
In particular, it was felt that a viral delivery sys-
tem using some of the newer modified approaches
would be advantageous given the one-off nature of
the surgery compared to the relative complexity of the
neurosurgery needed to implant the infusion delivery
systems used in the recent GDNF trial and conse-
quent requirement for on-going infusions. That said,
the efficacy of GDNF may require intermittent rather
than continuous RET receptor stimulation and, whilst
in the development phase, understanding the exact
dose administered and retaining the ability to reduce
and stop dosing may have utility. In addition, it
seems logical to assume that the individuals most
likely to benefit from such a treatment would be
those individuals with most neurons and fibres left
to rescue, namely patients with early stage PD with
evidence of fiber loss restricted to the dorsal striatum
[52]—where the therapeutic agent would be targeted.
If such an approach were recommended, then ensur-
ing the patient actually has Dopa-responsive PD will
be critical, and the use of imaging to help support
such a diagnosis would be essential, including both
DA imaging as well possibly fluorodeoxyglucose
(FDG) PET (for both diagnostic stratification and cor-
roboration of functional target engagement) [53]. In
addition, the exclusion of certain genetic forms of
parkinsonism may be wise, for example GBA het-
erozygote patients, given that they progress more
quickly especially with pathology outside of the DA
nigrostriatal pathway [54, 55].
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Whether an adjunct therapy to up regulate Nurr1
would be required is still unclear given the clinical
data to date, but the preclinical data would suggest
this. However, there is no such agent that has yet
been identified with a safety profile that is accept-
able and even if one existed, questions still arise as
to how long such a therapy should be given. Coupled
to this is a need to better understand the optimal dose
of GDNF and volume of its distribution, to ensure
that the treatment has the best chance of showing a
clinical effect, and that this effect is the maximal one
that one could expect for that agent. Finally, since
E. coli cannot form seven disulphide bonds correctly
and glycosylate GDNF, the use of mammalian cells
to make GDNF should be considered if protein infu-
sions are being considered although this brings with
it major cost implications.
As to what any trial should look like, there is still
much debate as to what primary end-point should be
used and at what time point, and input from the patient
community on this will be vital going forward. How-
ever, this end point should reflect changes in those
clinical aspects of PD that respond to dopaminergic
interventions given this is the pathway being targeted
by these treatments. A double-blind sham surgery
trial would be the preferred design for future studies,
although whether more optimisation of the delivery
of GDNF should be carried out before such a trial is
undertaken is debatable. Overall there was a consen-
sus from the workshop, that longer trials may be better
for fully exploring whether this agent can mediate
neurorestoration and thus waiting at least 18 months
from the start of any therapeutic intervention would
increase the chances of seeing any such effects. In
addition, using composite end points may also have
some merit given that the use of any single one, such
as the UPDRS part III score, has limitations. As to
what that composite clinical end point should look
like is unclear as regulatory agencies are currently
not accepting these for licensing purposes. However,
one that has recently been proposed relating to the
recent Bristol GDNF trial, PDCORE, embraces good
quality on-time; activities of daily living and reflects
previous participant feedback [56].
In addition to the use of wild type GDNF and
NRTN given as protein deliveries or a gene ther-
apy, other similar approaches for treating PD were
also discussed. In pre-clinical studies, new GDNF
and NRTN mutants with improved diffusion and
stability have shown beneficial effects [57, 58]. Fur-
thermore, to overcome the limitations of some of
the pharmacokinetic properties of the GDNF and
NRTN proteins, a blood-brain-barrier penetrating
small molecule GDNF receptor agonist has recently
been developed. This compound activates RET-
dependent intracellular signaling cascades in DA
neurons both in vitro and in vivo and also stimulates
the release of dopamine in the mouse striatum—all of
which suggests that this agent could be a novel future
treatment of PD [59].
In this respect, cerebral dopamine neurotrophic
factor (CDNF) is a relatively recently discov-
ered endoplasmic reticulum (ER) located, but also
secreted, protein that protects and restores the func-
tion of DA neurons in rodent and non-human primate
models of PD and does so more effectively than
GDNF [60]. CDNF is very different from other
known trophic factors–it has a unique structure
and mode of action protecting neurons by inhibit-
ing cell death, regulating ER stress, the unfolded
protein response (UPR) and reducing inflammation
[61]. In addition, CDNF rescues only ER-stressed or
degenerating neurons and does not influence naı¨ve
healthy neurons. This agent is now the subject of
an EUH2020 funded phase I–II clinical trial in PD
patients (NCT03295786) [61].
CONCLUSIONS
This special workshop comprehensively covered
the studies evaluating GDNF and the related trophic
factor NRTN in PD both preclinically and clinically.
It critically appraised the work so that conclusions
could be drawn as towhat has been shown andwhat
has not been shown with these agents. It was gen-
erally agreed that GDNF and NRTN have worked
relatively well in neurotoxic animal models of PD
but that their translation to the clinic has so far failed
to show a major impact—perhaps highlighting the
predictive limitations of toxin animal models being
commonly used in the preclinical space in PD and the
way we plan clinical trials.
Clinically, there is evidence that these neurotrophic
factors are able to rescue the expression of TH in the
human PD brain with some suggestion of a clinical
correlate. Nevertheless, the current size of any such
effect is not competitive compared to what is already
clinically available for the DA-related features of PD
(DuoDopa®; deep brain stimulation; lesion surgery
such as pallidotomy; apomorphine pumps, etc.) and
this may also be the case with new agents that are cur-
rently being trialled in PD around dopamine rescue
(stem cell derived DA neurons; CDNF, “dopamine”
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gene therapies). However, it must be realised that
these agents are uniquely designed to restore and
regenerate the dopaminergic pathway which is very
different from these other symptomatic therapies.
In conclusion, further work is needed to under-
stand better what can be achieved with GDNF and
related factors in the clinic to improve the lives of
patients with PD, although ultimately whether it will
ever have a competitive place for treating people with
PD remains unclear.
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